Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial

OBJECTIVES: Primary study outcome was absence of treatment failure (virological failure, VF, or treatment interruption) per protocol at week 48. METHODS: Patients on 3-drug ART with stable HIV-1 RNA <50 copies/mL and CCR5-tropic virus were randomized 1:1 to maraviroc with darunavir/ritonavir qd (...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossetti, Barbara, Gagliardini, Roberta, Meini, Genny, Sterrantino, Gaetana, Colangeli, Vincenzo, Re, Maria Carla, Latini, Alessandra, Colafigli, Manuela, Vignale, Francesca, Rusconi, Stefano, Micheli, Valeria, Di Biagio, Antonio, Orofino, Giancarlo, Ghisetti, Valeria, Fantauzzi, Alessandra, Vullo, Vincenzo, Grima, Pierfrancesco, Francisci, Daniela, Mastroianni, Claudio, Antinori, Andrea, Trezzi, Michele, Lisi, Lucia, Navarra, Pierluigi, Canovari, Benedetta, D’Arminio Monforte, Antonella, Lamonica, Silvia, D’Avino, Alessandro, Zazzi, Maurizio, Di Giambenedetto, Simona, De Luca, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697828/
https://www.ncbi.nlm.nih.gov/pubmed/29161288
http://dx.doi.org/10.1371/journal.pone.0187393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697828/
https://www.ncbi.nlm.nih.gov/pubmed/29161288
http://dx.doi.org/10.1371/journal.pone.0187393

Ejemplares similares